Content area

|
|

Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen

Et superficielt spredende melanom.
Forfatter(e)
Tessa Bystrup Boyles1, Inge Marie Svane2, Lars Bastholt3 & Henrik Schmidt1 1) Onkologisk Afdeling, Aarhus Universitetshospital 2) Center for Cancer og Immunterapi, Herlev Hospital 3) Onkologisk Afdeling, Odense Universitetshospital Ugeskr Læger 2016;178:V02160126
Reference: 
Ugeskr Læger 2016;178:V02160126
Blad nummer: 
Sidetal: 
2-5
Treatment of BRAF-mutated metastatic melanoma
Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was con­sidered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the com­bi­n­ation of the inhibitors, many patients develop acquired resistance within a year.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Julius Vindbjerg Nissen | 14/08
1 Kommentar
af Ulrich Fredberg | 14/08
1 Kommentar
af Karen Flink Konstantin-Hansen | 13/08
3 kommentarer
af Susanne Mejlby Nielsen | 06/08
4 kommentarer
af Gunvor Kramshøj Larsen | 04/08
28 kommentarer
af Olaf Bjarne Paulson | 03/08
1 Kommentar
af Hanne Hulgaard | 02/08
4 kommentarer
af Christian Stefan Legind | 28/07
1 Kommentar
af Connie Lærkholm Hansen | 23/07
1 Kommentar